Read more on P-BCMA-ALLO1 “showing promise in multiple myeloma” as featured in GEN | View our supporting IMS data here

Highlighted significant research, preclinical advances and platform technology progress at third annual R&D Day Appointed Kristin Yarema , Ph.D., as President, Cell Therapy , adding extensive oncology and allogeneic T cell immunotherapy experience to the Company’s leadership team SAN DIEGO , May 9,